Vertex Pharmaceuticals (VRTX)

SG&A Expense Growth

17.93%

Quarterly · Period ending:

VRTX logo

VRTX SG&A Expense Growth

Latest reported17.93%
VRTX Quarterly SG&A Growth (QoQ) (0.00% → 17.93%)
High-resolution chart · PNG

VRTX sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Vertex Pharmaceuticals SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
35.7524%
-6.2648%
22.2222%
-1.7272%
0.7567%
-21.3333%
31.25%
16.3636%
-5.1724%
-1.6949%
22.9167%
14.2857%
27.2727%
-10.8108%
32.1429%
7.6923%
18.1818%
-8.3333%
33.3333%
-5.2632%
5.5556%
-14.2857%
23.5294%
0%
6.25%
-85.5856%
7.767%
0.9804%
15.9091%
-6.383%
28.7671%
30.3571%
27.2727%
12.8205%
8.3333%
500%
-80%
20%
13.6364%
4.7619%
0%
0%
0%
0%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.